Formulation and characterization of metformin hydrochloride orodispersible tablets with super disintegrants

Abstract

Metformin hydrochloride's fast onset of action is very desirable, making it a prime candidate for the preparation of orodispersible tablets in the present study. This medication is prescribed for the management of type 2 diabetes, which does not respond to insulin. The tablets were made using direct compression and a mixture of the super disintegrants sodium starch glycolate (SSG) and croscarmellose sodium (CCS). Mannitol is a sugar-based excipient that serves as a binding agent, dissolves well in water, and provides a pleasant mouth feel. The blend's pre-compression results show that the medication excipients work well together and have desirable compression characteristics. Eight distinct formulations with varying amounts of SSG, CCS, and Mannitol were made. The properties of the tablets' drug release were measured, including their in vitro disintegration time, water absorption ratio, mechanical stability, wetting time, and so on. When using a greater concentration of SSG, CCS, and Mannitol, formulations F4 and F8 showed shorter in vitro disintegration times of 10.2 and 7.8 s, respectively, and formulation F8 showed 99.65% in vitro drug release at the end of 30 min. The orodispersible tablet performance can be enhanced through direct compression using the super disintegrants inclusion methodology.

Keywords

Orodispersible tablets / Metformin hydrochloride / Croscarmellose sodium

References

[1] Pramela RA, Archana N, Siva TP. Formulation and Evaluation of Orodispersible Metformin HCl tablets: a comparative study of isphagula husk and crospovidone as superdisintegrants. Int J Appl Pharm. 2010; 2: 15- 21.

[2] Patil C, Das S. Effect of various superdisintegrants on the drug release profile and disintegration time of Lamotrigine orally disintegrating tablets. Africa J Pharm Pharmacol. 2011; 5: 76- 82.

[3] Lakshmi CSR, Sagar PA, Anup VT, Jitesh JC, Nitesh JP, Vedhavati SV. Development and characterization of melt-in mouth tablets of Atenolol by sublimation technique. Int J Pharmaceut Res Dev. 2011; 3: 27- 36.

[4] Ruhil S, Dahiya M, Kaur H, Singh J. New insights into the disintegration mechanism and disintegration profiling of rapidly disintegrating tablets (RDTs) by thermal imaging. Int J Pharm. 2022;611, 121283.

[5] Habib W, Khankari R, Hontz J. Fast-dissolving drug delivery systems, critical review in therapeutics. D Car Systems. 2000; 17: 61- 72.

[6] Chang RK, Guo X, Burnside B, Couch R. Fast-dissolving tablets. Pharmaceut Technol. 2000; 24: 52- 58.

[7] Galal EM, Mona HAE, Nermeen AE. Formulation and evaluation of Meloxicam orally dispersible capsules. J Pharmaceut Sci. 2009; 4: 8- 22.

[8] Gupta MS, Kumar TP. Characterization of orodispersible films: an overview of methods and introduction to a new disintegration test apparatus using LDR-LED sensors. J Pharmaceut Sci. 2020; 109: 2925- 2942.

[9] Hofmanova JK, Mason J, Batchelor HK. Tribology provides an in vitro tool that correlated to in vivo sensory data on the mouthfeel of coated tablets. Int J Pharm. 2021;597, 120323.

[10] Naman S, Madhavi N, Singh B, Madan J, Baldi A. Implementing risk-based quality by design for development and optimization of flavored oral disintegrating mini tablets. J Drug Deliv Sci Technol. 2021;66, 102799.

[11] Jashanjit S, Rajmeet S. Optimization and formulation of orodispersible tablets of Meloxicam. Trop J Pharmaceut Res. 2008; 8: 153- 159.

[12] Radke RS, Jadhav JK, Chajeed MR. Formulation and evaluation of orodispersible tablets of Baclofen. Inter J Chemic Tech Res. 2009; 1: 517- 521.

[13] Kulkarni MS, Zeeshan A. Formulation and evaluation of orodispersible tablet of ornidazole. Int J Pharmaceut Sci Res. 2010; 1: 39- 47.

[14] Avani RG, Sanjay BP. Formulation and Evaluation of Orodispersible tablets of Ondansetron Hydrochloride by direct compression using superdisintegrants. Inter J Phar Scien Nano. 2008; 106: 106- 111.

[15] Howida KI, Doaa AES. Valsartan orodispersible tablets: formulation, In vitro/In vivo characterization. AAPS Pharm Scien Tech. 2010; 11: 189- 196.

RIGHTS & PERMISSIONS

2023 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).